US 11,685,781 B2
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
Ezio Bonvini, Potomac, MD (US); Ling Huang, Bethesda, MD (US); Chia-Ying Kao Lam, San Jose, CA (US); Gurunadh Reddy Chichili, Buffalo Grove, IL (US); Ralph Froman Alderson, North Potomac, MD (US); Paul A. Moore, North Potomac, MD (US); and Leslie S. Johnson, Rockville, MD (US)
Appl. No. 16/966,960
Filed by MacroGenics, Inc., Rockville, MD (US)
PCT Filed Feb. 13, 2019, PCT No. PCT/US2019/017772
§ 371(c)(1), (2) Date Aug. 3, 2020,
PCT Pub. No. WO2019/160904, PCT Pub. Date Aug. 22, 2019.
Claims priority of provisional application 62/738,632, filed on Sep. 28, 2018.
Claims priority of provisional application 62/631,043, filed on Feb. 15, 2018.
Prior Publication US 2021/0155694 A1, May 27, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2815 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C07K 16/3038 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 33 Claims
 
1. A Disease Antigen×CD3 (DA×CD3) Binding Molecule comprising a CD3-Binding Domain capable of binding an epitope of CD3 and a Disease Antigen-Binding Domain capable of binding an epitope of CD123, wherein said CD3-Binding Domain comprises:
(A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:99;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:58;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:59;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:60;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:61; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:62.